Arcus Biosciences (RCUS) Projected to Post Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is expected to be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.8912) per share and revenue of $22.2150 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.10). The business had revenue of $17.00 million during the quarter, compared to analyst estimates of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.Arcus Biosciences’s revenue was down 39.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.14) EPS. On average, analysts expect Arcus Biosciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $28.18 on Monday. The firm has a market capitalization of $3.54 billion, a P/E ratio of -8.86 and a beta of 0.80. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. The company has a 50 day moving average price of $27.00 and a 200 day moving average price of $24.07. Arcus Biosciences has a 52 week low of $8.84 and a 52 week high of $31.74.

Insider Buying and Selling

In other news, CFO Robert C. Goeltz II sold 7,763 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $25.63, for a total transaction of $198,965.69. Following the sale, the chief financial officer owned 84,161 shares of the company’s stock, valued at $2,157,046.43. This trade represents a 8.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 20,067 shares of Arcus Biosciences stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $28.62, for a total transaction of $574,317.54. Following the transaction, the president directly owned 822,240 shares of the company’s stock, valued at approximately $23,532,508.80. This trade represents a 2.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 110,325 shares of company stock valued at $3,174,319 over the last ninety days. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. acquired a new position in shares of Arcus Biosciences in the fourth quarter worth about $39,000. Strs Ohio purchased a new position in shares of Arcus Biosciences in the 1st quarter valued at about $67,000. Tower Research Capital LLC TRC increased its stake in shares of Arcus Biosciences by 184.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after purchasing an additional 5,476 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in Arcus Biosciences in the 2nd quarter worth about $97,000. Finally, Corient Private Wealth LLC acquired a new position in Arcus Biosciences in the 2nd quarter worth about $180,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Wall Street Analysts Forecast Growth

RCUS has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Friday, July 17th. Leerink Partners set a $47.00 price target on shares of Arcus Biosciences in a report on Monday, April 20th. Lifesci Capital assumed coverage on shares of Arcus Biosciences in a research note on Thursday, June 4th. They set an “outperform” rating and a $46.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Monday, May 11th. Finally, Truist Financial initiated coverage on Arcus Biosciences in a research report on Monday, May 18th. They issued a “buy” rating and a $35.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.40.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.